Area of research
Oncology · Hepatology
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Hepatocellular Carcinoma Treatment and Prognosis, Gastric Cancer Management and Outcomes, and Cancer Treatment and Pharmacology.
Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment
Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment.
Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma
Targeting the liver: Insights from a tertiary center on post-operative hepatic arterial oxaliplatin for metastatic colorectal cancer
Lung-only metastatic pancreatic cancer: Differences in patients ‘characteristics, molecular profile and survival
EORTC-1203 GITC "INNOVATION": Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: Overall survival results.
What are the outcomes for long-term survivors after esophagectomy ? - Evidence from a randomized controlled trial (FFCD9901).
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
<i>KRAS</i>, a New Target for Precision Medicine in Colorectal Cancer?
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
Supplementary Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
Supplementary Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
Supplementary Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
Supplementary Data from Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer.
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.
Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI).
Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
The consensus molecular subtypes of colorectal cancer
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1